CSL, uniQure one-time hemophilia B gene therapy becomes most expensive drug at $3.5M

Nov. 23, 2022 4:48 AM ETuniQure N.V. (QURE), CSLLY, CMXHFBLUEBy: Ravikash, SA News Editor6 Comments

Biotechnology Molecular Engineering DNA Genetic Manipulation


CSL (OTCPK:CSLLY) (OTCPK:CMXHF) has priced its one-time gene therapy Hemgenix for hemophilia B at $3.5M, making it the most expensive medicine in the world, Reuters reported.

On Tuesday, the U.S. Food and Drug Administration (FDA) approved uniQure (NASDAQ:QURE) and

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.